From Flexion Snags Pfizer Bucks, Three Pharma Deals, For New Drug Model:

clayman

clayman—

Mike Clayman is CEO of Flexion Therapeutics.

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
How Healthy Are Your Market Access Programs?
A Guide to Performing Check-ups on Pharmaceutical Distribution & Patient Access Programs
Archbow Consulting

Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes

From Our Editors · Special Report
Xcelerating Life Sciences Philadelphia: Special Report
Becoming the Cell & Gene Therapy Hub

Xconomy on Demand

We offer a number of ways to subscribe for free!